For people with early-stage lung cancer (stages IB, II, or IIIA), surgery is often the first step. But what if you could boost the body's own defenses against the cancer before the operation? This study tested exactly that. Doctors gave patients a drug called pembrolizumab—a type of immunotherapy that helps the immune system recognize and attack cancer cells—both before and after surgery. The idea was to see if this approach was practical and safe. The main thing they wanted to know was simple: after getting the drug first, could patients still go through with their planned surgery? The study enrolled 35 people to find out. The researchers also wanted to look closely at what the drug does to the immune system. They focused on special immune cells called tumor-infiltrating lymphocytes (TILs), which are like the body's soldiers that can move into a tumor. The theory was that pembrolizumab might 'unmask' these cells, helping them recognize and target the cancer. While pembrolizumab is already approved for advanced lung cancer, using it around surgery for earlier stages was new. This trial was a crucial step to see if this two-part strategy—treatment before and after an operation—is something doctors can realistically offer patients.
Can immunotherapy before lung cancer surgery help the immune system fight the tumor?
Plain Language Summary
What this means for you:
A study tested giving immunotherapy before and after lung cancer surgery to see if it was a feasible approach. What this means for you:
A study tested giving immunotherapy before and after lung cancer surgery to see if it was a feasible approach. View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Non-small Cell Lung Carcinoma
Intervention(s): Pembrolizumab (DRUG)
This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells. Pembrolizumab has been approved for the treatment of advanced lung cancer, but is investigational in this setting.
Detailed: The presumed mechanism of action for pembrolizumab is the removal of T lymphocyte inhibition by masking the PD-1 receptor. Our hypothesis is that the masking of the PD-1 receptor by pembrolizumab results in the activation and proliferation of T lymphocytes with specificities against tumor associated antigens (TILs). In untreated lung cancer tumors, we would expect few tumors to have TIL cells with specificities against tumor associated antigens. Based on the response rate to pembrolizumab in advanced lung cancer, we hypothesize that at least 20% of lung cancers would have TIL cells with specificities against tumor associated antigens after pembrolizumab therapy.
Studying neoadjuvant pembrolizumab therapy is an attractive strategy for studying the immunologic changes caused by PD-1 (progra
Primary Outcome(s): Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab
Enrollment: 35 (ACTUAL)
Lead Sponsor: Neal Ready MD PhD
Start: 2017-01 | Primary Completion: 2019-03-19
Results posted: 2020-02-18